Drug Trial Radar · NCT07608705
A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jun 8, 2026
Primary completion
Aug 24, 2026
Study completion Aug 24, 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.
Conditions
- Hyperlipidemias
Interventions
HRS-1301 TabletsDrug
HRS-1301 tablets.
Atorvastatin Calcium TabletsDrug
Atorvastatin Calcium tablets.
Midazolam oral solutionDrug
Midazolam oral solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 15 days.
- Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-last)Time frame: Up to 15 days.
- Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)Time frame: Up to 15 days.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 18 days.
- Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-last)Time frame: Up to 18 days.
- Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)Time frame: Up to 18 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.